A dedicated MBG LC-MS method to detect and identify MBG in pregnant women plasma samples was developed. The presence of endogenous marinobufagenin in pregnant women was confirmed due to the high speciﬁcity of the distinct 7 mass transitions used in this LC-MS/MS assay. The promising results suggest privileging MBG detection via such instrumental technique eliminating confusion with former marinobufagenin-like material.
Thomas et al, 2017, Diagnostic and Prognostic Research, 1:17
A method to express positive and/ or negative predictive value (PPV/NPV) criteria within the ROC space is presented. An example on the prediction of pre-eclampsia risk in low-risk nulliparous pregnancies is elaborated
Presented at EU MSACL 2019, Sept 22-26th , Salzburg Austria
We evaluated the suitability of a protein free substitute for plasma or serum, Serasub™ as a surrogate matrix for the preparation of calibrators for PrePsia™ – a screening test to predict the risk of preterm preeclampsia in early pregnancy.
Presented at the International Society for the Study of Hypertension in Pregnancy (ISSHP), 24-26th Sept 2015, Budapest, Hungary
A prototype LC/Ms assay was confirmed as a viable platform for the multiplex analysis of metabolite biomarker relevant to the prediction of pre-eclampsia. Stratification of low risk nulliparous pregnant women into high or low risk groups for pre-eclampsia at 15 weeks gestation was possible in multimarker models.
Presented at MSACL EU, Salzburg, September 2-5 th 2014
A sensitive LC-MS assay was developed which allowed the authentication of MBG in human plasma. This method, once fully developed, will help quantify MBG plasma levels in early pregnancy as these levels increase with the manifestation of pre-eclampsia.